-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Upgrades Crescent Biopharma to Buy, Announces $36 Price Target

Benzinga·10/06/2026 10:20:01
HC Wainwright & Co. analyst Mitchell S. Kapoor upgrades Crescent Biopharma (NASDAQ:CBIO) from Neutral to Buy and announces $36 price target.